A New Case Series Suggests That SCA48 (ATX/STUB1) Is Primarily a Monogenic Disorder.

ataxia genetics

Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
07 Jul 2024
Historique:
revised: 27 05 2024
received: 19 04 2024
accepted: 17 06 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

Monoallelic, pathogenic STUB1 variants cause autosomal dominant cerebellar ataxia (ATX-STUB1/SCA48). Recently, a genetic interaction between STUB1 variants and intermediate or high-normal CAG/CAA repeats in TBP was suggested, indicating digenic inheritance or a disease-modifying role for TBP expansions. To determine the presence and impact of intermediate or high-normal TBP expansions in ataxic patients with heterozygous STUB1 variants. We describe 21 patients with ataxia carrying a heterozygous STUB1 variant and determined TBP repeat length. A total of 15 of 21 patients (71%) carried a normal TBP SCA48 is predominantly a monogenic disorder, because most patients carried an isolated, heterozygous STUB1 variant and presented with the typical combined phenotype of ataxia and cognitive dysfunction. Still, co-occurrence of TBP

Sections du résumé

BACKGROUND BACKGROUND
Monoallelic, pathogenic STUB1 variants cause autosomal dominant cerebellar ataxia (ATX-STUB1/SCA48). Recently, a genetic interaction between STUB1 variants and intermediate or high-normal CAG/CAA repeats in TBP was suggested, indicating digenic inheritance or a disease-modifying role for TBP expansions.
OBJECTIVE OBJECTIVE
To determine the presence and impact of intermediate or high-normal TBP expansions in ataxic patients with heterozygous STUB1 variants.
METHODS METHODS
We describe 21 patients with ataxia carrying a heterozygous STUB1 variant and determined TBP repeat length.
RESULTS RESULTS
A total of 15 of 21 patients (71%) carried a normal TBP
CONCLUSIONS CONCLUSIONS
SCA48 is predominantly a monogenic disorder, because most patients carried an isolated, heterozygous STUB1 variant and presented with the typical combined phenotype of ataxia and cognitive dysfunction. Still, co-occurrence of TBP

Identifiants

pubmed: 38973070
doi: 10.1002/mds.29912
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Références

Genis D et al. Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48). Neurology 2018;91(21):e1988.
Shi Y et al. Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia. PLoS One 2013;8(12):e81884.
Roux T, Barbier M, Papin M, et al. Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment. Genet Med 2020;22(11):1851–1862.
Park J, Deininger N, Rautenberg M, et al. Correspondence on "clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment" by Roux et al. Genet Med 2021;23(6):1171–1172.
Lieto M, Riso V, Galatolo D, et al. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. Eur J Neurol 2020;27(3):498–505.
Magri S, Nanetti L, Gellera C, et al. Digenic inheritance of STUB1 variants and TBP polyglutamine expansions explains the incomplete penetrance of SCA17 and SCA48. Genet Med 2022;24(1):29–40.
Barbier M, Davoine CS, Petit E, et al. Intermediate repeat expansions of TBP and STUB1: genetic modifier or pure digenic inheritance in spinocerebellar ataxias? Genet Med 2023;25(2):100327.
Rossi M, Hamed M, Rodríguez‐Antigüedad J, et al. Genotype–phenotype correlations for ATX‐TBP (SCA17): MDSGene systematic review. Mov Disord 2023;38(3):368–377.
Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol 2021;89(2):212–225.
Cocozza S, Pontillo G, De Michele G, Perillo T, Guerriero E, Ugga L, et al. The "crab sign": an imaging feature of spinocerebellar ataxia type 48. Neuroradiology 2020;62(9):1095–1103.
Palombo F, Vaisfeld A, Tropeano VC, et al. Two more families supporting the existence of monogenic spinocerebellar ataxia 48. Neurogenetics 2024.
Mariotti C, Alpini D, Fancellu R, et al. Spinocerebellar ataxia type 17 (SCA17): oculomotor phenotype and clinical characterization of 15 Italian patients. J Neurol 2007;254(11):1538–1546.
Mongelli A, Magri S, Salvatore E, et al. Frequency and distribution of polyQ disease intermediate‐length repeat alleles in healthy Italian population. Neurol Sci 2020;41(6):1475–1482.
van derSanden B, Corominas J, deGroot M, et al. Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield. Genet Med 2021;23(8):1569–1573.
Gardiner SL, Boogaard MW, Trompet S, deMutsert R, Rosendaal FR, Gussekloo J, et al. Prevalence of carriers of intermediate and pathological Polyglutamine disease–associated alleles among large population‐based cohorts. JAMA Neurol 2019;76(6):650–656.

Auteurs

Teije H van Prooije (TH)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.

Maartje Pennings (M)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Lucille Dorresteijn (L)

Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands.

Thatjana Gardeitchik (T)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Vincent J J Odekerken (VJJ)

Department of Neurology, Amsterdam UMC, Amsterdam, the Netherlands.

Mayke Oosterloo (M)

Department of Neurology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, the Netherlands.

Annie Pedersen (A)

Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.

Corien C Verschuuren-Bemelmans (CC)

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Alexander Vrancken (A)

Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.

Erik-Jan Kamsteeg (EJ)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Bart P C van de Warrenburg (BPC)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.

Classifications MeSH